Neurotrope, Inc. (NTRP)
| Market Cap | 22.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.35M |
| Shares Out | 23.78M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Dec 1, 2021 |
| Last Price | $0.941 |
| Previous Close | $1.050 |
| Change ($) | -0.109 |
| Change (%) | -10.38% |
| Day's Open | 1.040 |
| Day's Range | 0.915 - 1.040 |
| Day's Volume | 500,213 |
| 52-Week Range | 0.713 - 1.470 |
News
NEW YORK and MANALAPAN TOWNSHIP, N.J., Sept. 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused o...
NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"...
Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP) gap-opened sharply higher on above 50 times average volume following a corporate update from the company.
It may be unusual to see a stock rise close to 100% without a corporate buyout, but in biotech and emerging pharmaceutical companies gains of that size can occur simply with a drug study updat...
Shares of Neurotrope Inc. NTRP, -77.95% plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company said its Alzheimer's dis...
Shares of thinly-traded nano-cap biotech Neurotrope Inc (NASDAQ: NTRP) were plummeting Monday following an adverse clinical trial readout.
Neurotrope has been struggling lately, but the selling pressure may be coming to an end soon.
Investors need to pay close attention to Neurotrope (NTRP) stock based on the movements in the options market lately.
The biotechnology sector is generally considered the most volatile and riskiest sector within all of healthcare.
Neurotrope, Inc. may be a winner by default in the battle against Alzheimer’s disease after shares of Biogen Inc. suffered handily with the announcement that it and partner Eisei were halting ...
About NTRP
Neurotrope, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Jun... [Read more...]
| Industry Biotechnology | Founded 2012 |
| CEO Charles Ryan | Employees 5 |
| Stock Exchange NASDAQ | Ticker Symbol NTRP |